^
Association details:
| Biomarker: | ALK fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug Class: | ALK inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
[Ceritinib as First-line Treatment for Advanced Lung Adenocarcinoma with COX7A2L-ALK Fusion: A Case Report and Literature Review]
Published date:
04/20/2023
Excerpt:
...22 cases of rare ALK fusion were reported in 19 articles….The objective response rate (ORR) was 82.6% (19/23) and disease control rate (DCR) was 95.7% (22/23) for rare ALK fusions patients treated with ALK inhibitors. Lung adenocarcinoma patients with rare ALK fusion could benefit from ALK inhibitors.
DOI:
10.3779/j.issn.1009-3419.2023.102.15
